- Home
- HLXB vs RIGL Comparison
HLXB vs RIGL Comparison
Compare HLXB & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLXB
- RIGL
- Stock Information
- Founded
- HLXB 2021
- RIGL 1996
- Country
- HLXB United States
- RIGL United States
- Employees
- HLXB N/A
- RIGL N/A
- Industry
- HLXB
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HLXB
- RIGL Health Care
- Exchange
- HLXB NYSE
- RIGL Nasdaq
- Market Cap
- HLXB 244.6M
- RIGL 291.9M
- IPO Year
- HLXB 2024
- RIGL 2000
- Fundamental
- Price
- HLXB $10.43
- RIGL $16.04
- Analyst Decision
- HLXB
- RIGL Buy
- Analyst Count
- HLXB 0
- RIGL 4
- Target Price
- HLXB N/A
- RIGL $31.13
- AVG Volume (30 Days)
- HLXB 10.2K
- RIGL 222.4K
- Earning Date
- HLXB 01-01-0001
- RIGL 11-05-2024
- Dividend Yield
- HLXB N/A
- RIGL N/A
- EPS Growth
- HLXB N/A
- RIGL N/A
- EPS
- HLXB N/A
- RIGL N/A
- Revenue
- HLXB N/A
- RIGL $130,201,000.00
- Revenue This Year
- HLXB N/A
- RIGL $38.26
- Revenue Next Year
- HLXB N/A
- RIGL $24.21
- P/E Ratio
- HLXB N/A
- RIGL N/A
- Revenue Growth
- HLXB N/A
- RIGL 7.48
- 52 Week Low
- HLXB $10.03
- RIGL $7.10
- 52 Week High
- HLXB $10.83
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- HLXB N/A
- RIGL 66.62
- Support Level
- HLXB N/A
- RIGL $15.51
- Resistance Level
- HLXB N/A
- RIGL $16.85
- Average True Range (ATR)
- HLXB 0.00
- RIGL 0.89
- MACD
- HLXB 0.00
- RIGL 0.07
- Stochastic Oscillator
- HLXB 0.00
- RIGL 70.08
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.